News articles about Amyris (NASDAQ:AMRS) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2992833769009 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Synthetic Biology Market Development, Growth Scenario, Global Leading Players, 2018 Competitive Analysis and … (medgadget.com)
- Financial Analysis: Pacific Ethanol (PEIX) & Amyris (AMRS) (americanbankingnews.com)
- Hot Stocks to Observe: Amyris, Inc. (NASDAQ:AMRS), The Goldfield Corporation (NYSE:GV), US Auto Parts Network … (journalfinance.net)
- Enthralling Stocks: Amyris, Inc. (NASDAQ:AMRS), XpresSpa Group, Inc. (NASDAQ:XSPA), Achieve Life Sciences, Inc … (thestreetpoint.com)
- Amyris (AMRS) Presents At 19th Annual B. Riley FBR Investor Conference – Slideshow (seekingalpha.com)
Several equities analysts have commented on AMRS shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Amyris in a report on Monday, April 2nd. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. ValuEngine downgraded Amyris from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. BidaskClub downgraded Amyris from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 17th. Finally, B. Riley set a $10.00 price target on Amyris and gave the company a “buy” rating in a report on Tuesday, March 20th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.13.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($1.31). The firm had revenue of $23.00 million for the quarter, compared to analyst estimates of $24.12 million. The company’s revenue was up 77.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.13) EPS. research analysts forecast that Amyris will post -1.92 earnings per share for the current fiscal year.
In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the firm’s stock in a transaction on Monday, May 7th. The shares were sold at an average price of $6.54, for a total value of $622,359.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 21.80% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.